Earnings Summary

Immunovant Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2024. On a quarterly growth basis, Immunovant Inc has generated -100% fall in its revenue since last 3-months.

Immunovant Inc’s net profit fell -17.87% since last year same period to $-87.15Mn in the Q2 2024. On a quarterly growth basis, Immunovant Inc has generated -15.71% fall in its net profits since last 3-months.

Immunovant Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2024. On a quarterly growth basis, Immunovant Inc has generated -Inf% fall in its net profit margins since last 3-months.

Immunovant Inc’s earning per share (EPS) estimates for the current quarter stand at -0.53 - a -23.26% fall from last quarter’s estimates.

Immunovant Inc’s earning per share (EPS) estimates for the current year stand at -0.53.

Immunovant Inc’s earning per share (EPS) fell -5.26% since last year same period to -0.6 in the Q2 2024. This indicates that the Immunovant Inc has generated -5.26% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Immunovant Inc’s return on assets (ROA) stands at -0.4.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Immunovant Inc’s return on equity (ROE) stands at -0.65.